| 54.33 Real-Time Quote |  -0.41 / -0.75%Today’s Change | 39.93 Today|||52-Week Range 58.41 | +10.16% Year-to-Date |
| Priority FDA Review for Celgene's Abraxane - Analyst Blog 10:54am / Zacks.com | Lilly Scraps Oncology Candidate - Analyst Blog May 13 / Zacks.com |
| US doctors paid $1bn by top drug companies May 22 / FT.com | Novo Nordisk / Lundbeck: drugs start working May 01 / FT.com |
| Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) May 21 / TheStreet.com | Investors: Look beyond Merck's patent loss May 01 / Money |
| Amgen to Set Up JV in China - Analyst Blog May 14 / Zacks.com | US pharma: spot the difference Apr 29 / FT.com |
| Big Cap Pharma Is Turning Up May 14 / StockTwits |
| Previous close | 54.74 |
| Today’s open | 54.50 |
| Day’s range | 53.91 - 54.50 |
| Volume | 1,709,441 |
| Average volume (3 months) | 5,076,181 |
| Market cap | $61.7B |
| Dividend yield | 3.61% |
| Earnings growth (last year) | -6.15% |
| Earnings growth (this year) | +15.51% |
| Earnings growth (next 5 years) | -1.20% |
| Revenue growth (last year) | -6.93% |
| P/E ratio | 13.0 |
| Price/Sales | 2.43 |
| Price/Book | 4.24 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +0.11 | +0.29% |
| AZNAstraZeneca PLC | -0.13 | -0.25% |
| CELGCelgene Corp | -1.61 | -1.30% |
| NVONovo Nordisk A/S | -0.97 | -0.57% |
| Next reporting date | July 24, 2013 |
| EPS forecast (this quarter) | $1.00 |
| Annual revenue (last year) | $22.6B |
| Annual profit (last year) | $4.1B |
| Net profit margin | 18.09% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer, CFO & EVP-Global Services Derica W. Rice, MBA |
Vice President- Biotechnology Discovery Research Thomas F. Bumol, PhD |
Corporate headquarters Indianapolis, Indiana |
.
